In Q1 2026, Vivos reported revenue of approximately $5.1 million, up 70% year over year, driven mainly by sleep testing services and its SCN acquisition. On June 10, 2026, Vivos entered into a Collaboration Agreement with South Palm Cardiovascular Associates to form AIM Florida, a management services organization providing administrative, operational, billing, payer-contracting, marketing and other support services to affiliated professional clinical entities that will deliver sleep apnea diagnostic and treatment services.
Cyborg Score Rationale
Vivos shows strong revenue growth (70% YoY in Q1 2026) and FDA clearances for differentiated products, but faces profitability challenges with widening net losses ($7.8M in Q1) despite 60% gross margins. Strategic expansions and insurance coverage gains suggest momentum, but capital constraints and integration costs require careful monitoring.
Top Insights
(May 2026) Q1 2026 revenue grew 70% YoY to $5.1M with 60% gross margins, but net losses widened to $7.8M driven by integration costs from The Sleep Center of Nevada acquisition
(May 2026) Oral appliance unit sales grew 42% to 5,304 units in Q1 2026, with expansion and insurance in-network status expected to drive further growth
(June 2026) Vivos announced collaboration with South Palm Cardiovascular Associates to launch AIM Florida with projected $6M+ annual revenue, targeting sleep apnea care for cardiovascular patients
(June 2026) Vivos announced binding agreement for senior debt and intent to file registration statement for rights offering to address capital needs
Named Competitors
CPAP/BiPAP devices — Market-leading positive airway pressure devices for OSA treatment
Sleep and respiratory solutions — Respironics devices and sleep diagnostic systems
Oral appliance devices — Custom-fitted oral appliances for mild-to-moderate OSA
Recent Developments
(June 2026) Collaboration with South Palm Cardiovascular Associates to form AIM Florida management services organization targeting Florida sleep apnea market
(June 2026) Senior debt binding agreement and rights offering announcement to strengthen balance sheet
(May 2026) Q1 2026 results: $5.1M revenue (+70% YoY), $7.8M net loss, 42% unit sales growth
(January 2026) Collaboration with SoundHealth to expand access to FDA-cleared allergy and sleep technologies
Open the full interactive Vivos Therapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.